Hualan Biological Vaccine Inkomsten in het verleden
Verleden criteriumcontroles 1/6
Hualan Biological Vaccine's earnings have been declining at an average annual rate of -3.6%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 0.06% per year. Hualan Biological Vaccine's return on equity is 8.2%, and it has net margins of 30.2%.
Belangrijke informatie
-3.6%
Groei van de winst
-6.9%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 11.3% |
| Inkomstengroei | -0.06% |
| Rendement op eigen vermogen | 8.2% |
| Nettomarge | 30.2% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Hualan Biological Vaccine (SZSE:301207) Seems To Use Debt Rather Sparingly
Oct 08
Potential Upside For Hualan Biological Vaccine Inc. (SZSE:301207) Not Without Risk
Jul 25Hualan Biological Vaccine's (SZSE:301207) Upcoming Dividend Will Be Larger Than Last Year's
Jun 11Revenue Downgrade: Here's What Analysts Forecast For Hualan Biological Vaccine Inc. (SZSE:301207)
Apr 03Hualan Biological Vaccine Inc. Just Missed Revenue By 9.2%: Here's What Analysts Think Will Happen Next
Apr 02Hualan Biological Vaccine Inc.'s (SZSE:301207) Subdued P/E Might Signal An Opportunity
Apr 01An Intrinsic Calculation For Hualan Biological Vaccine Inc. (SZSE:301207) Suggests It's 31% Undervalued
Mar 04Opbrengsten en kosten
Hoe Hualan Biological Vaccine geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 1,650 | 498 | 719 | 100 |
| 30 Jun 24 | 2,296 | 777 | 1,021 | 87 |
| 31 Mar 24 | 2,300 | 805 | 999 | 81 |
| 31 Dec 23 | 2,410 | 860 | 1,040 | 91 |
| 30 Sep 23 | 1,984 | 645 | 859 | 96 |
| 30 Jun 23 | 915 | 330 | 285 | 103 |
| 31 Mar 23 | 1,956 | 614 | 856 | 128 |
| 01 Jan 23 | 1,826 | 520 | 805 | 135 |
| 30 Sep 22 | 1,997 | 598 | 856 | 146 |
| 30 Jun 22 | 2,879 | 948 | 1,207 | 148 |
| 31 Mar 22 | 1,833 | 624 | 640 | 148 |
| 01 Jan 22 | 1,830 | 621 | 649 | 144 |
| 30 Sep 21 | 2,608 | 1,004 | 1,015 | 146 |
| 30 Jun 21 | 2,441 | 922 | 960 | 155 |
| 31 Mar 21 | 2,439 | 934 | 960 | 125 |
| 31 Dec 20 | 2,426 | 925 | 959 | 111 |
| 31 Dec 19 | 1,049 | 375 | 346 | 73 |
| 31 Dec 18 | 803 | 270 | 381 | 53 |
| 31 Dec 17 | 285 | -77 | 216 | 64 |
Kwaliteitswinsten: 301207 has high quality earnings.
Groeiende winstmarge: 301207's current net profit margins (30.2%) are lower than last year (32.5%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 301207's earnings have declined by 3.6% per year over the past 5 years.
Versnelling van de groei: 301207's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 301207 had negative earnings growth (-22.8%) over the past year, making it difficult to compare to the Biotechs industry average (0.08%).
Rendement op eigen vermogen
Hoge ROE: 301207's Return on Equity (8.2%) is considered low.